Log in or Register for enhanced features | Forgotten Password?
White Papers | Suppliers | Events | Report Store | Companies | Dining Club | Medical Devices | Videos
Automation
IT & Software
Return to: PBR Home | Automation | IT & Software

IT & Software

Beryllium develops MCL-1 platform for structure-guided drug discovery Beryllium, a scientific research services company engaging in collaborations with commercial and academic partners, announced the development of an MCL-1 platform for structure-guided drug discovery.
Automation > IT & Software > News
Generex, NHTherapeutics team up to use RapidMist Buccal delivery technology for Leuprolide By PBR Staff Writer
Generex Biotechnology (GNBT) announced that it has entered into a Memorandum of Understanding with NHTherapeutics, pursuant to which the companies will co-develop a formulation for the delivery of Leuprolide into the human body via the buccal mucosa using the Generex proprietary RapidMist buccal drug delivery system.
Automation > IT & Software > News Quintiles introduces new solution to meet needs of biopharmaceutical firms in Asia-Pacific To help Asia-Pacific emerging biopharmaceutical companies achieve their growth aspirations, Quintiles today launched a new solution set tailored to meet the needs of emerging companies in the world’s most diverse and dynamic healthcare market.
Automation > IT & Software > News
See more IT & Software news

Latest IT & Software News and Insight

View all IT & Software news or find news targeted to your interests
Highland Therapeutics gets three US patents and one notice of allowance
Highland Therapeutics, a pharmaceutical company, announced that the US Patent and Trademark Office (USPTO) has issued three patents and one Notice of Allowance (NOA) for the Company’s lead products.
Automation > IT & Software > News
FDA accepts Tris Pharma's NDA for Dyanavel XR to treat ADHD
By PBR Staff Writer
The US Food and Drug Administration (FDA) has accepted for review Tris Pharma's new drug application (NDA) for Dyanavel XR (amphetamine) CII, an Extended-Release Oral Suspension, for the treatment of attention deficit hyperactivity disorder (ADHD).
Automation > IT & Software > News
Biomay to use VTU Pichia strains to produce recombinant allergens
By PBR Staff Writer
Austrian biotech companies VTU Technology and Biomay have entered into a licensing agreement for the production of recombinant allergens.
Automation > IT & Software > News
vTv Therapeutics begins Phase III trial of azeliragon to treat mild Alzheimer's disease
By PBR Staff Writer
US-based biopharmaceutical firm vTv Therapeutics has enrolled the first patient in its Phase III placebo controlled trial (Steadfast) of azeliragon, an oral antagonist of the Receptor for Advanced Glycation Endproducts (RAGE) to treat mild Alzheimer's disease (AD).
Automation > IT & Software > News
Corbus gets FDA nod to begin Phase II trial of Resunab to treat cystic fibrosis
By PBR Staff Writer
Corbus Pharmaceuticals has received clearance for its investigational new drug (IND) application from the US Food and Drug Administration (FDA) to begin a Phase II trial with Resunab to treat cystic fibrosis (CF), a chronic, life-threatening, genetic disease.
Automation > IT & Software > News
Kura Oncology begins dosing in Phase II tipifarnib trial to treat tumors with HRAS mutations
By PBR Staff Writer
US-based biopharmaceutical firm Kura Oncology has started dosing in the Phase II clinical trial of tipifarnib in patients with locally advanced tumors that carry HRAS mutations.
Automation > IT & Software > News
DURECT reports positive results from DUR-928 multi-dose phase I trial
DURECT has obtained positive results from a multi-dose Phase 1 clinical trial with an oral formulation of DUR-928, the lead molecule in DURECT's Epigenomic Regulator Program.
Automation > IT & Software > News
MTTI gets expanded patent approval for 99mTc-Duramycin technology to target programmed cell death
Molecular Targeting Technologies announces that the patent which it has exclusively licensed from the Medical College of Wisconsin (MCW), was granted by the patent office of the People’s Republic of China.
Automation > IT & Software > News
SanBio gets key patent from USPTO for new treatment for chronic stroke
SanBio, a regenerative medicine company leading the way in the development of cell-based biologics targeting neurological disorders, has been granted a key patent by the US Patent and Trademark Office (USPTO) covering its proprietary modified stem cells, SB623.
Automation > IT & Software > News
Amarantus enters into cGMP manufacturing deal with Catalent Biologics for MANF
Amarantus BioScience Holdings (AMBS), a biotechnology company focused on developing therapeutic and diagnostic products for neurological disorders and orphan indications, announced that it has entered into a manufacturing agreement with Catalent Pharma Solutions (CTLT), the leading global provider of advanced delivery technologies and development solutions for drugs, biologics and consumer health products, for clinical-grade production of MANF (mesencephalic-astrocyte-derived neurotrophic factor).
Automation > IT & Software > News
View all IT & Software news or find news targeted to your interests